Administering additional IL-6 or JAK inhibitors after patients have entered CARS may exacerbate immunoparalysis and increase the secondary infection risk [188], whereas the premature delivery of rIL-7 or GM-CSF during the cytokine storm peak can theoretically fuel hyperinflammation [153]. The gene discussed is IL6; the disease is infection.